Shanu Modi, MD discusses key results from the DESTINY-Breast11 trial for high-risk HER+ early breast cancer.

DESTINY-Breast11: Neoadjuvant Trastuzumab Deruxtecan Alone (T-DXd) or Followed by Paclitaxel + Trastuzumab + Pertuzumab (T-DXd-THP) vs SOC For High-Risk HER2+ Early Breast Cancer (eBC)

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.